TI
BIO icon

Turner Investments’s Bio-Rad Laboratories Class A BIO Stock Holding History

Turner Investments’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-600
Closed -$136K – 99
2017
Q2 		$136K Buy
+600
New +$131K 0.09% 221

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Turner Investments's BIO Position: Q3 2017 in Review

Turner Investments sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2017, closing a stake of 600 shares — an estimated $136K sold.

Turner Investments first reported a position in BIO in Q2 2017 and held it in 1 quarter. The position peaked at $136K in Q2 2017. 271 funds tracked by Wall St. Rank hold BIO as of Q3 2017.

  • Turner Investments reported no remaining Bio-Rad Laboratories Class A position as of Q3 2017 after selling out during the quarter.
  • Turner Investments sold 600 Bio-Rad Laboratories Class A shares in Q3 2017, an estimated $136K.
  • Turner Investments first reported a position in Bio-Rad Laboratories Class A in Q2 2017 and held it in 1 quarter.
  • Turner Investments's Bio-Rad Laboratories Class A position peaked at $136K in Q2 2017.
  • 271 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2017.

Based on Turner Investments's 13F filing for Q3 2017, filed 8 Nov 2017.